Viking Therapeutics posts corporate presentation highlighting VK2735 obesity drug program pipeline
VKTX•Corporate presentation highlights VK2735 and pipeline updates
Viking Therapeutics highlighted VK2735, a GLP-1/GIP dual agonist for obesity, with the VANQUISH Phase 3 registration program underway.
- The company expects Phase 3 obesity studies for oral VK2735 to begin in 4Q26.
- Oral VK2735 Phase 2a VENTURE study showed up to 12.2% mean weight loss at Week 13; placebo-adjusted weight loss reached 10.9%.
- Exploratory maintenance dosing showed continued weight loss when down-titrating from 90 mg to 30 mg through Week 13.
- Pipeline update included VK3019 in Phase 1 for obesity; VK2809 completed a successful Phase 2b VOYAGE trial in MASH.
